

Haematologica
HAEMATOL/2016/151894
Version 4

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher risk myelodysplastic syndrome with 5q deletion.
Results of a phase II study by the Groupe Francophone Des Myelodysplasies

Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, Christian Recher, Romain Guieze, Emmanuel Raffoux, Krimo Bouabdallah, Mathilde Hunault, Eric Wattel, Laure Stalnikiewicz, Andrea Toma, Herve' Dombret, Nobert Vey, Marie Sebert, Claude Gardin, Cendrine Chaffaut, Sylvie Chevret, and Pierre Fenaux

Disclosures: Celgene (Paris, France) provided Lenalidomide and a scientific grant, but was not involved in trial analysis or manuscript writing.

Contributions: L.A., P.F. and S.C. conceived the study. L.A., S.C., and P.F. collected the data. L.A., S.C. and P.F. drafted the manuscript; S.C and C.C. did the statistical analysis, LA, TP, AS, CR, RG, ER, KB, MH, EW, LS, AT, HD, NV, MS, CG enrolled the patients, collected the data and approved the manuscript.